M any of the previous randomized trials comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary artery disease (MVD) reported clinical outcomes at 5-year follow-up, suggesting equivalent or better survival with CABG as compared with PCI. 1-13 However, the rate of saphenous vein graft failure was reported to be high beyond 5 years after CABG, 14,15 although a long-term survival advantage of internal thoracic artery grafts compared with saphenous vein grafts was reported to increase with time ≤15 years after CABG. 16, 17 Furthermore, late adverse cardiac events, both related and unrelated to the target lesion, were reported to occur without attenuation ≤20-year follow-up after PCI using bare-metal stent (BMS). 18 Therefore, 5-year follow-up may be too short to evaluate the true differences in long-term clinical outcomes between PCI and CABG. One might expect further Background-Many of the previous randomized trials comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary artery disease reported equivalent or better survival with CABG as compared with PCI at 5-year follow-up. However, 5-year follow-up might be too short to evaluate the true differences in long-term clinical outcomes between PCI and CABG. Methods and Results-Among 8934 patients enrolled in the extended 10-to 14-year follow-up study of the CREDO-Kyoto registry cohort-1 (Coronary Revascularization Demonstrating Outcome study in Kyoto) conducted in the bare-metal stent era, 5152 (PCI: n=3490 and CABG: n=1662) patients had multivessel coronary artery disease without left main disease. Median follow-up duration was 11.2 (interquartile range: 10.2-12.2) years. The cumulative 10-year incidence of all-cause death was not significantly different between PCI and CABG (32.2% versus 31.7%; log-rank P=0.93). After adjusting for confounders, however, the mortality risk of PCI was significantly higher than that of CABG (hazard ratio, 1.19 [95% confidence interval, 1.02-1.39]; P=0.03). Within 5 years after the index procedure, the risk for all-cause death was significantly higher after PCI than after CABG (hazard ratio, 1.41; 95% CI, 1.12-1.79; P=0.004). By a landmark analysis at 5 years, however, the cumulative 10-year incidence of and adjusted risk for all-cause death beyond 5 years were not significantly different between PCI and CABG (19.3% versus 20.0%; log-rank P=0.22 and hazard ratio, 1.02, 95% confidence interval, 0.83-1.26; P=0.82). Conclusions-CABG as compared with PCI was associated with better 10-year survival in patients with multivessel coronary artery disease. However, the benefit of CABG compared with PCI on late mortality beyond 5 years was not observed in this study. (Circ Cardiovasc Interv. 2016;9:e003365.
Very Long-Term Outcome in Multivessel CAD survival advantage of CABG using internal thoracic artery grafts compared with PCI with follow-up longer than 5 years. However, there are only 2 studies in the balloon angioplasty era 9, 12 and only 1 small study in the BMS era 19 reporting very long-term (≥10 years) outcome after CABG as compared with PCI for MVD. Therefore, we sought to evaluate very long-term (10 to 14 year) outcomes after PCI versus CABG in patients with MVD in a large Japanese observational database of patients who underwent first coronary revascularization (PCI or CABG) in the BMS era.
Methods

Study Population
The CREDO-Kyoto registry cohort-1 (Coronary Revascularization Demonstrating Outcome study in Kyoto) is a multicenter registry enrolling consecutive patients undergoing first coronary revascularization between January 2000 and December 2002, excluding those patients with acute myocardial infarction within a week before the index procedure. The 3-year clinical outcomes comparing PCI with CABG have been reported previously. 20 In the current report, we extended the follow-up up to at least 10 years to investigate very longterm (10 to 14 year) outcomes of PCI compared with CABG for MVD. Among 9877 patients (PCI: N=6878 and CABG: N=2999), a total of 943 patients were excluded from the extended very longterm follow-up study (484 patients who underwent a combined noncoronary surgery; 407 patients from 5 centers not participating in the extended study; 48 patients who refused to participate in the study when contacted for follow-up; and 4 patients included in the original cohort who were revealed to have had the exclusion criteria for the registry [acute myocardial infarction within a week before the index procedure]). After excluding 895 patients with left main coronary artery disease and 2887 patients with single vessel disease, the current study population consisted of 5152 patients with MVD (PCI: N=3490 and CABG: N=1662; Figure 1 ). The relevant ethics committees in all 26 participating centers approved the research protocol (Appendix A in the Data Supplement). Because of retrospective enrollment, written informed consent was waived for patients; however, patients who refused to participate in the study when contacted for follow-up were excluded. This strategy is concordant with the guidelines of the Japanese Ministry of Health, Labor and Welfare.
Definitions and Data Collection for Baseline Characteristics
Experienced clinical research coordinators from the independent clinical research organization (Research Institute for Production Development, Kyoto, Japan; Appendix B in the Data Supplement) collected demographic, angiographic, and procedural data from hospital charts or databases according to the prespecified definitions. Baseline clinical characteristics, such as previous myocardial infarction (MI), heart failure, diabetes mellitus, hypertension, current smoker status, atrial fibrillation, chronic obstructive pulmonary disease, and malignancy were regarded as present when these diagnoses were recorded in the hospital charts. Stroke at baseline included asymptomatic stroke detected by noninvasive imaging modalities. Peripheral vascular disease was regarded to be present when carotid, aortic, or other peripheral vascular disease were being treated or scheduled for surgical or endovascular interventions. Elderly patients were defined as those ≥75 years of age. Left ventricular ejection fraction was measured either by contrast left ventriculography or echocardiography. Patients with left ventricular ejection fraction ≤40% were regarded as having left ventricular dysfunction. Chronic kidney disease was regarded as present when creatinine clearance estimated by Cockcroft-Gault formula was <60 mL/min. Anemia was defined as blood hemoglobin level <12 g/dL.
Clinical End Points and Data Collection for Follow-Up Events
The primary outcome measure in this study was all-cause death. The secondary outcome measures included cardiovascular death, sudden death, noncardiovascular death, MI, stroke, and any coronary revascularization. Death was regarded as cardiovascular in origin unless obvious noncardiovascular causes could be identified. Any death during the index hospitalization was regarded as cardiovascular death. MI was adjudicated according to the definition in the Arterial Revascularization Therapy Study. 21 Within 1 week of the index procedure, only Q-wave MI was adjudicated as MI. Stroke at follow-up was defined as symptomatic stroke. Any coronary revascularization was defined as either PCI or CABG for any reason. Scheduled staged coronary revascularization procedures performed within 3 months of the initial procedure were not regarded as follow-up events but were included in the index procedure. Collection of follow-up information was mainly conducted through review of inpatient and outpatient hospital charts by the clinical research coordinators, and additional follow-up information was collected through contact with patients, relatives, and referring physicians by sending mail with questions about vital status and subsequent hospitalizations. Clinical events were adjudicated by an independent clinical event committee (Appendix C in the Data Supplement). The detailed definitions of clinical events in this registry were described previously. 20
Statistical Analysis
Categorical variables were presented as number and percentage and were compared with the χ 2 test. Continuous variables were expressed as mean±SD or median with interquartile range. Continuous variables were compared using the Student's t test or Wilcoxon rank-sum test based on their distributions. Cumulative incidence was estimated by the Kaplan-Meier method, and differences were assessed with the log-rank test. Cumulative incidence estimators of events accounting for competing risk were also calculated. The effects of PCI relative to CABG for the individual end points were expressed as hazard ratios (HR) and their 95% confidence intervals (CI). In consistent with our previous report, 20 we estimated the HR by Cox proportional hazard models adjusting for 30 clinically relevant factors listed in Table 1 . We also computed the adjusted event curves of the 2 groups (PCI and CABG) using the methods described by Ghali et al. 22 Continuous
WHAT IS KNOWN
• Many of the previous randomized trials comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary artery disease reported clinical outcomes at 5-year follow-up, suggesting equivalent or better survival with CABG as compared with PCI.
• However, very long-term (≥10 years) clinical outcomes after CABG as compared with PCI have not been fully evaluated yet, especially after introduction of coronary stents.
WHAT THE STUDY ADDS
• CABG as compared with PCI was associated with better 10-year survival in patients with multivessel coronary artery disease.
• However, the benefit of CABG compared with PCI on late mortality was observed only during the first 5 years of follow-up. variables were dichotomized by clinically meaningful reference values or median values. Proportional hazard assumptions for the variables were assessed on the plots of log (time) versus log [-log (survival)] stratified by the variables, and the assumptions were verified to be acceptable for the risk-adjusting variables. To evaluate late clinical outcomes beyond 5 years, we conducted a landmark analysis at 5 years. Those patients having individual end point event within 5 years were excluded from the landmark analysis. As a prespecified subgroup analysis, the risk for all-cause death was compared between PCI and CABG stratified by age (≥75 years and <75 years), diabetic status (diabetes mellitus and non-diabetes mellitus), the extent of coronary artery disease (2-and 3-vessel disease), and the existence of chronic total occlusion (presence or absence of chronic total occlusion). The same Cox proportional hazard models adjusting for 29 variables excluding the subgroup factor were used in each subgroup analyses. We also evaluated the interaction between the subgroup factors and the risk of PCI relative to CABG for all-cause death. Because the issues of selection biases and unmeasured confounders are inherent limitations of observational studies, a propensity score-matching analysis was conducted as a sensitivity analysis (Appendix D in the Data Supplement).
All statistical analyses were conducted using JMP 8.0 software (SAS Institute, Inc, Cary, NC) and SAS 9.4 (SAS Institute, Inc, Cary, NC). All reported P values were 2 tailed, and P values <0.05 were considered statistically significant.
Results
Baseline Characteristics
The PCI group more often had patients with advanced age, higher body mass index, hypertension, and malignancy, whereas the CABG group more often included patients with left ventricular dysfunction, heart failure, previous MI, diabetes mellitus, stroke, peripheral vascular disease, chronic kidney disease, and anemia (Table 1) .
Regarding the complexity of coronary artery anatomy, the CABG group included more patients with severe coronary artery disease, such as triple-vessel disease, involvement of proximal left anterior descending coronary artery, and total occlusion. However, nearly half of patients with triple vessel disease were treated by PCI in the present study. Patients in the CABG group underwent more complete revascularization as indicated by the number of vessels revascularized. In the PCI group, stent implantation was performed in 85% of patients. In the CABG group, at least 1 IMA graft was used in 95% of patients and off-pump surgery was performed in 42% of the patients (Table 1) .
Antiplatelet agents and evidence-based medicines, such as statins, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and β-blockers were more often prescribed in the PCI group than in the CABG group, although the prescription rates of evidence-based medicines in the present study were low from the current standard ( Figure 2 ). After adjusting for confounders, however, the excess mortality risk of PCI relative to CABG was significant (HR, 1.19; 95% CI, 1.02-1.39; P=0.03; Table 2 and Figure 2 ; Table I in the Data Supplement). The excess adjusted risk of PCI relative to CABG for ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker, CABG, coronary artery bypass grafting; ITA, internal thoracic artery; LAD, left anterior descending coronary artery; and PCI, percutaneous coronary intervention.
*Risk-adjusting variables selected for Cox proportional hazard models. Very Long-Term Outcome in Multivessel CAD cardiovascular death was also significant, whereas the adjusted risk of PCI relative to CABG for noncardiovascular death was neutral. The excess risk of PCI relative to CABG for MI was also significant, whereas the risk for stroke tended to be lower in the PCI group than in the CABG group. The excess risk of PCI relative to CABG for any coronary revascularization was pronounced and statistically highly significant ( Table 2 and Figure 3 ). The extremely high rate of any coronary revascularization (41.4%) within the first year after PCI was mainly driven by restenosis leading to target-lesion revascularization (TLR; TLR: 33.4% and non-TLR: 17.8%).
Late Clinical Outcomes Beyond 5-Year After Coronary Revascularization
The patients included in the landmark analysis beyond 5-year were less sick than the entire cohort of patients (Table II in the Data Supplement). Within 5 years after the index procedure, the risk for all-cause death was significantly higher after PCI than after CABG (HR, 1.41; 95% CI, 1.12-1.79; P=0.004; Table 2 and Figure 4 ; Table III in the Data Supplement). By a landmark analysis at 5 years, however, the cumulative 10-year incidence of and adjusted risk for all-cause death beyond 5 years was not significantly different between PCI and CABG (19.3% versus 20.0%; log-rank P=0.22 and HR: 1.02; 95% CI, 0.83-1.26; P=0.82; Table 2 and Figure 4 ; Table IV in the Data Supplement). The adjusted risks of PCI relative to CABG for cardiovascular death, sudden death, noncardiovascular death, MI, and stroke were also neutral beyond 5 years. However, the excess risk of PCI relative to CABG for any coronary revascularization remained significant even beyond 5 years, although the effect size beyond 5 years was attenuated as compared with that within 5 years ( Table 2 and Figure 3 ). Beyond 5 years after PCI, the majority of coronary revascularization procedures were non-TLR rather than TLR (TLR: 6.4% and non-TLR: 16.5%).
Sensitivity Analyses Using Propensity Score-Matched Cohort
Baseline characteristics of the PCI and CABG groups in the propensity score-matched cohort were much more comparable than those in the entire cohort ( 
Subgroup Analyses
For the subgroup analysis according to age, the cumulative 10-year incidence of all-cause death tended to be higher in the PCI group than in the CABG group in patients ≥75 years of age, whereas it was significantly lower in the PCI group than in the CABG group in patients <75 years of age. After adjusting confounders, the excess mortality risk of PCI relative to CABG was significant in patients ≥75 years of age (HR: 1.39; 95% CI: 1.07-1.81; P=0.01), whereas the risk was neutral in patients <75 years of age (HR, 1.10; 95% CI, 0.90-1.34; P=0.35). However, there was no interaction between the mode of revascularization (PCI or CABG) and age (interaction P=0.26; Table 3 ). The mortality risk of PCI relative to CABG was not significant regardless of diabetic status, extent of coronary artery disease (2-vessel disease and 3-vessel disease), and existence of chronic total occlusion (Table 3 ). 
Discussion
The main findings of this study were as follows: (1) PCI as compared with CABG was associated with higher long-term (>10 years) mortality in patients with MVD; (2) the late mortality risk of PCI relative to CABG was neutral beyond 5-year up to 14-year after the procedure.
Previous randomized trials comparing PCI with CABG in the era of balloon angioplasty and BMS have suggested similar long-term survival ≤5 years in patients with MVD except for patients with diabetes mellitus or advanced age (≥65 years) in whom mortality was lower after CABG as compared with PCI. 1,3-5,9-13 However, the subsequent trials comparing PCI with CABG in the era of drug-eluting stents (DES) mostly enrolled high-risk patients with diabetes mellitus and triplevessel disease have demonstrated significantly lower mortality ≤5 years after CABG as compared with PCI. 2, [6] [7] [8] 23 The current observational study including a large proportion of diabetic and elderly patients also suggested a survival benefit of CABG compared with PCI at 5-year follow-up. In this study, the degree of coronary revascularization seemed to be more complete in the CABG group than in the PCI group. Achievement of more complete revascularization in the CABG group than in the PCI group might potentially benefit MVD patients with better midterm survival. Cumulative incidences were estimated by the Kaplan-Meier method. Cumulative 10-year, 5-year, and 5-to 10-year incidences were presented for entire follow-up, within 5 year, and beyond 5 year, respectively. Number of events included the events that occurred until the end of follow-up for entire follow-up, and beyond 5 year. The effects of PCI relative to CABG for the individual end points were expressed as hazard ratios and their 95% confidence intervals. CABG indicates coronary artery bypass grafting; and PCI, percutaneous coronary intervention.
Cumulative incidence estimator is accounted for competing risk of *noncardiovascular death, †nonsudden death, ‡cardiovascular death, or §all-cause death.
Regarding the clinical outcomes beyond 5 years, there are only 3 studies reporting very long-term (≥10 years) outcome after CABG as compared with PCI. 9, 12, 19 In the BARI (Bypass Angioplasty Revascularization Investigation), which was the largest study among the 3 trials, the survival rates were similar after PCI using balloon angioplasty and CABG both at 5-year and 10-year follow-up. 9, 24 However, the BARI trial conducted in prestent era included only <40% of patients with significant proximal left anterior descending coronary artery lesions, which is markedly different from the current CABG practice. In the present large, observational study enrolling consecutive patients in the real clinical practice, the prevalence of significant proximal left anterior descending coronary artery lesions was 74% in the PCI group and 94% in the CABG group with at least 1 internal thoracic artery graft use in 95% and BMS use in 85% of patients. Despite the higher risk profiles of patients in the present study, the mortality risk of PCI relative to CABG was neutral beyond 5 years up to 14 years after the procedure in consistent with the BARI trial result. The survival benefit of CABG compared with PCI was mainly observed within 5 years but not beyond 5 years after coronary revascularization. In daily clinical practice, therefore, selection of revascularization strategies based on the 5-year clinical trial results may be appropriate even considering the longer-term outcomes.
In a previous meta-analysis, patient age modified the effect of CABG relative to PCI on mortality, with hazard ratios of 1.25 (0.94-1.66) in patients aged <55 years, 0.90 (0.75-1.09) in patients aged 55 to 64 years, and 0.82 (0.70-0.97) in patients aged ≥65 years (P=0.002 for interaction). 1 PCI might be a reasonable option in patients <65 years. Longer-term outcomes are particularly relevant in patients undergoing coronary revascularization at young age. In the present study, PCI as compared with CABG was associated with similar very long-term mortality in nonelderly patients <75 years of age.
One of the possible reasons for the neutral mortality risk between PCI and CABG beyond 5-year might be related to the patient age. Mean age at the time of enrollment was 66.9 years in PCI patients eligible for follow-up beyond 5 years as compared with 68.1 years in the entire PCI cohort. Therefore, the neutral mortality risk between PCI and CABG beyond 5 years could be reflecting the neutral very long-term mortality risk in nonelderly patients as mentioned above. Another possible reason for the attenuation of the treatment effect of CABG 
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relative to PCI beyond 5 years in the present study might be related to the use of newer treatment modalities with improved outcome such as the use of DES at the time of subsequent coronary revascularization during long-term follow-up. Regarding the clinical outcomes other than all-cause death, the excess risk of PCI relative to CABG for MI and repeated coronary revascularization was significant both at 5 years and at 10 years. However, the risk for MI between PCI and CABG beyond 5 years was neutral, which might be one of the reasons for neutral mortality risk beyond 5 years. Also, it was intriguing to note that the higher risk of PCI relative to CABG for repeated coronary revascularization was somewhat attenuated beyond 5 years. The extremely high rate of repeated coronary revascularization was one of the most bothering issues of PCI using BMS in patients with MVD. The advent of DES has markedly reduced TLR for restenosis, whereas non-TLR, either because of incomplete revascularization or new lesion formation, remains to be an important issue of contemporary PCI using DES.
Study Limitations
There are several limitations in this study. First, in this observational study, selection bias and unmeasured confounders might have affected the study results despite the appropriate statistical adjustment for potential confounders. Second, we used the baseline data as the risk-adjusting variables for the 5-year landmark analysis. Clinical characteristics and . Comparison of all-cause death between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) within and beyond 5 y by the 5 y landmark analysis. Crude (A) and adjusted (B) incidence curves for all-cause death. Very Long-Term Outcome in Multivessel CAD medication use might have changed during the initial 5-year period, which were not evaluated in the present study. Third, it is unknown whether the observed neutral mortality risk beyond 5 years despite higher early (within 5 years) mortality risk of PCI relative to CABG is the true phenomenon or related to the observational study design. The change of medical and interventional treatment during long-term follow-up might affect the clinical outcomes in both PCI and CABG patients. The patients included in the landmark analysis beyond 5 years were less sick than the entire cohort of patients. This might reflect attrition of high-risk patients in whom selection bias was more likely to be present, having influenced the 5-year outcomes. The finding in the present study should be confirmed with extended follow-up of those trials demonstrating lower 5-year mortality with CABG in the DES era. Forth, the long-term outcome of the MVD patients in this study might be different from that of the patients treated in the current clinical practice, because the indication of coronary revascularization and the interventional, surgical, and medical treatment have changed over time. Considering the complexity of CABG patients in the DES era, it could be possible that CABG might continue to confer the survival advantage compared with PCI beyond 5 years. Finally, because patient demographics, practice patterns including the selection of revascularization procedure and medical therapy, and clinical outcomes in patients undergoing PCI and CABG in Japan might be different from those outside Japan. The extremely high rate of repeated revascularization after PCI might, at least in part, be related to scheduled follow-up coronary angiography, which is still commonly performed in Japan. Generalizing the current study results to populations outside Japan should be done with caution.
Conclusions
CABG as compared with PCI was associated with better 10-year survival in patients with MVD. However, the benefit of CABG compared with PCI on late mortality beyond 5 years after coronary revascularization was not observed in the present study. Cumulative 10-y incidence was estimated by the Kaplan-Meier method. Number of events included the events that occurred until the end of follow-up. CABG indicates coronary artery bypass grafting; and PCI, percutaneous coronary intervention.
